OGSIVEO FDA approval date

The FDA approved OGSIVEO on 27 Nov 2023.

FDA approval date
27 Nov 2023

Drug identity has not yet been verified against registry records

Also recorded as NIROGACESTAT HYDROBROMIDE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-11-27DayOGSIVEOFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA217677", "applicant_as_listed_by_fda": "SPRINGWORKS", "brand_names": ["OGSIVEO"], "active_ingredients": ["NIROGACESTAT HYDROBROMIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20231127", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026